Granisetron transdermal - Kyowa Kirin International

Drug Profile

Granisetron transdermal - Kyowa Kirin International

Alternative Names: Granisetron patch; Sancuso; SP-01 - Solasia Pharma

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator ProStrakan
  • Developer Kyowa Hakko Kirin; Kyowa Kirin International; Solasia Pharma
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
  • 24 Nov 2015 Solasia Pharma grants Lee's Pharma exclusive license to promote, commercialise and sell transdermal granisetron (Sancuso®) in the People's Republic of China
  • 23 Mar 2015 Phase-III development is ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top